Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tests fruquintinib for Tough-to-Treat colorectal cancer

NCT ID NCT06787105

Disease control Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study is observing how well the drug fruquintinib works for people with metastatic colorectal cancer who have already tried standard treatments. About 150 participants in Germany will be treated as part of their normal care, and researchers will track tumor response, survival, side effects, and quality of life. The goal is to see if fruquintinib helps control the disease in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fruquintinib
What this could lead to
If successful, this study could confirm that fruquintinib works well in everyday clinical practice for patients with advanced colorectal cancer who have run out of other options.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to 150 patients in Germany, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with mCRC receiving fruquintinib in Germany.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * Indication and decision for therapy with fruquintinib in accordance with the current German SmPC of fruquintinib as monotherapy for patients with mCRC. * Prior treatment with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF therapy, and if RAS wild-type, anti EGFR therapy. * Progression on or intolerance to treatment with either trifluridine/tipiracil and/or regorafenib. * Other criteria according to current SmPC. * Signed written informed consent.\* \* Patients are allowed to be enrolled up to 6 weeks after their first dose of fruquintinib. These patients cannot participate in the PRO assessments. Exclusion Criteria: * Participation in an interventional clinical trial (except follow-up) within 30 days prior to enrollment or start of treatment with fruquintinib, whatever comes first. * Contraindications according to current SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colorectal cancer (MCRC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic colorectal cancer (MCRC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    42 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ambulantes Zentrum für Hämatologie & Onkologie

    RECRUITING

    Cottbus, Brandenburg, 03046, Germany

  • BAG / Onkologische Gemeinschaftspraxis

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • BAG Onkologie am Filmpark

    RECRUITING

    Potsdam, Brandenburg, 14482, Germany

  • DRK Kliniken Berlin Köpenick Klinik für Allgemein-, Viszeral- & Minimalinvasive Chirurgie

    RECRUITING

    Berlin, 12559, Germany

  • Dr. Vehling-Kaiser MVZ GmbH Landshut

    RECRUITING

    Landshut, Bavaria, 84036, Germany

  • Evang. Kliniken Essen-Mitte (KEM) Internistische Onkologie

    RECRUITING

    Essen, North Rhine-Westphalia, 45136, Germany

  • Evangelisches Waldkrankenhaus Spandau Innere Medizin I

    RECRUITING

    Berlin, 13589, Germany

  • Gemeinschaftspraxis Dr. Haytham Kamal und Dr. David C. Dorn

    RECRUITING

    Hanover, Lower Saxony, 30625, Germany

  • Gemeinschaftspraxis Dr. Mohm / Dr. Siklaky / Mann

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie GbR

    RECRUITING

    Lebach, Saarland, 66822, Germany

  • Hämatologie - Onkologie - Stolberg

    RECRUITING

    Stolberg, North Rhine-Westphalia, 52222, Germany

  • Hämatologie und Onkologie München-Pasing MVZ GmbH

    RECRUITING

    München, Bavaria, 81241, Germany

  • Hämatologikum Biberach

    RECRUITING

    Biberach, Baden-Wurttemberg, 88400, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

    RECRUITING

    Hamburg, 20249, Germany

  • KHOP - Kalkan Hämatologie Onkologie Palliativmedizin

    RECRUITING

    Wermelskirchen, North Rhine-Westphalia, 42929, Germany

  • Klinikum Rosenheim Medizinische Klinik II

    RECRUITING

    Rosenheim, Bavaria, 83022, Germany

  • MVZ Kloster Paradiese GbR Schwerpunktpraxis für Hämatologie u Onkologie

    RECRUITING

    Soest, North Rhine-Westphalia, 59494, Germany

  • MVZ Onko Medical GmbH

    RECRUITING

    Neustadt am Rübenberge, Lower Saxony, 31535, Germany

  • MVZ am Klinikum Aschaffenburg GmbH

    RECRUITING

    Aschaffenburg, Bavaria, 63768, Germany

  • MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbH

    RECRUITING

    Cologne, North Rhine-Westphalia, 50677, Germany

  • MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum

    RECRUITING

    Ravensburg, Baden-Wurttemberg, 88212, Germany

  • MVZ für Onkologie und Urologie GmbH

    RECRUITING

    Wilhelmshaven, Lower Saxony, 26389, Germany

  • Onkologie Hof MVZ GmbH

    RECRUITING

    Hof, Bavaria, 95028, Germany

  • Onkologie UnterEms Leer-Emden-Papenburg Dr. L. Müller

    RECRUITING

    Leer, Lower Saxony, 26789, Germany

  • Onkologische Schwerpunktpraxis

    RECRUITING

    Heidelberg, Baden-Wurttemberg, 69115, Germany

  • Onkologische Schwerpunktpraxis

    RECRUITING

    Hanover, Lower Saxony, 30161, Germany

    Contact Email: •••••@•••••

  • Onkologische Schwerpunktpraxis Speyer

    RECRUITING

    Speyer, Rhineland-Palatinate, 20077, Germany

  • Onkozentrum Dresden

    RECRUITING

    Dresden, Saxony, 01127, Germany

  • Praxis Dr. Michl

    RECRUITING

    München, Bavaria, 81479, Germany

  • Praxis Dr. med. Jens Uhlig

    RECRUITING

    Naunhof, Saxony, 04683, Germany

  • Praxis Internistischer Onkologie und Hämatologie (PIOH)

    RECRUITING

    Frechen, North Rhine-Westphalia, 50226, Germany

  • Praxis für Hämatologie und internistische Onkologie

    RECRUITING

    Ratingen, North Rhine-Westphalia, 40878, Germany

  • Praxis für interdisziplinäre Onkologie & Hämatologie

    RECRUITING

    Freiburg im Breisgau, Baden-Wurttemberg, 79110, Germany

  • Praxis und Tagesklinik für Hämatologie/Onkologie

    RECRUITING

    Zittau, Saxony, 02763, Germany

  • SHG Klinikum Idar-Oberstein Med. Klinik I: Gastroenterologie, Nephrologie, Hämatologie, Onkologie

    RECRUITING

    Idar-Oberstein, Rhineland-Palatinate, 55743, Germany

  • Schwerpunktpraxis Hämatologie & Internistische Onkologie

    RECRUITING

    Fürth, Bavaria, 90766, Germany

  • Schwerpunktpraxis und Tagesklinik für Hämatologie und Onkologie

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • Universitätsklinikum Ulm Klinik für Innere Medizin I Gastroenterologie, Nephrologie

    RECRUITING

    Ulm, Bavaria, 89081, Germany

  • Zentrum Ambulante Onkologie

    RECRUITING

    Schorndorf, Baden-Wurttemberg, 73614, Germany

  • ze:ro Praxen MVZ für Innere Medizin Weinheim

    RECRUITING

    Weinheim, Baden-Wurttemberg, 69469, Germany

  • ÜBAG Onkologische Kooperation Harz GbR

    RECRUITING

    Goslar, Lower Saxony, 38642, Germany

  • Überörtliche Gemeinschaftspraxis Schwerpunkt Haematologie, internist Onkologie & Palliativmedizin

    RECRUITING

    Hamburg, 20259, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.